FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)																		
Name and Address of Reporting Person * McGuire Jonathan Will				2. Issuer Name and Ticker or Trading Symbol SECOND SIGHT MEDICAL PRODUCTS INC [EYES]							C _	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director							
(Last) (First) (Middle) 12744 SAN FERNANDO ROAD, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 03/14/2017										Chief Ex	xecutive Off	icer			
(Street) SYLMAR, CA 91342				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)		(State)	(Zip)				Ta	ble I - N	on-Deri	ivativ	e Securitie	s Acquir	ed, D	isposed of	, or Benefic	cially Owne	d		
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, any (Month/Day/Yea		Date, if	(Instr. 8)		(A (I	4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		Owned Followir Transaction(s) (Instr. 3 and 4)		ecurities Beneficially ng Reported		Ownership Form: Be Direct (D) or Indirect (I)		eneficial wnership	
Common Stock 0			03/14/2017	03/14/2017			Code A		,794	٨	Price \$ 1.47	59,79	98			D	str. 4)		
Reminder: R	eport on a se	parate line for each o						f t o	Persons his for current	m are ly va		ired to r ontrol n	respo	ond unles er.		n containe n displays		SEC 14	74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	ction	5. Num	tive ies ed	6. Date Expirat		of Year) of Se			7. Title and Amount of Underlying Securities			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	(Instr. 4)
				Code	V	(A)	(D)	Date Exercis	sable		xpiration ate	Title		Amount or Number of Shares					
Warrant to Purchase Common Stock	\$ 1.47	03/14/2017		A		6,794 (1)		03/14	4/2017	03	3/14/2022	Comn		6,794	(1)	6,794		D	
Non- Qualified Stock Option (right to buy)	\$ 1.97							01/03	/2018 [©]	2) 03	1/03/2027	, Comn Stoc	non ek	571,330		571,330	0	D	
Non- Qualified Stock Option (right to buy)	\$ 4.10							01/21/	/2017 [©]	2) 02	1/21/2026	Comn		21,290		21,290)	D	
Non- Qualified Stock Option (right to buy)	\$ 12.43							08/17	/2016 [©]	08	8/17/2025	Comn		420,000		420,000	0	D	
Restricted Stock Unit (RSU)	(3)							08/17/	/2016 [©]	2) 08	8/17/2019	Comn		190,000		118,750	0	D	

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
McGuire Jonathan Will 12744 SAN FERNANDO ROAD SUITE 400 SYLMAR, CA 91342			Chief Executive Officer					

Signatures

/s/ Jonathan Will McGuire	03/16/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Common stock and warrants reported on this Form 4 pursuant to an exercise of subscription rights previously distributed by the Company to all holders of the Company's common stock. Each (1) stockholder received a right to invest \$0.47 for every share held of record on February 10, 2017, the record date, to purchase units consisting of one share of common stock and one warrant to purchase one share of common stock. The final allocation numbers of units were distributed on March 14, 2017.
- (2) Options and RSUs vest over a 4 year term, with 25% vesting on the date exercisable as set forth in this Form 4 and thereafter vesting in 12 equal quarterly installments of 6.25%.
- (3) Each restricted stock unit represents a contingent right to receive one share of common stock of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.